Walleye Capital
LXEO icon

Walleye Capital’s Lexeo Therapeutics LXEO Stock Holding History

Walleye Capital’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-73,868
Closed -$344K – 6094
2026
Q2 		$344K Buy
+73,868
New +$400K ﹤0.01% 3056
2025
Q1 		– Sell
-61,930
Closed -$407K – 4738
2024
Q4 		$407K Buy
+61,930
New +$488K ﹤0.01% 3153

Other funds holding LXEO

Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Walleye Capital's LXEO Position: Q3 2026 in Review

Walleye Capital sold out of Lexeo Therapeutics (LXEO) in Q3 2026, closing a stake of 73,868 shares — an estimated $344K sold.

Walleye Capital first reported a position in LXEO in Q4 2024 and held it in 2 quarters. The position peaked at $407K in Q4 2024. 97 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • Walleye Capital reported no remaining Lexeo Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 73,868 Lexeo Therapeutics shares in Q3 2026, an estimated $344K.
  • Walleye Capital first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 2 quarters.
  • Walleye Capital's Lexeo Therapeutics position peaked at $407K in Q4 2024.
  • 97 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.